Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elite Pharmaceuticals ( (ELTP) ) has shared an announcement.
Elite Pharmaceuticals has received approval from the Israeli Ministry of Health for its generic version of Adderall®, designed to treat ADHD and narcolepsy. The company will partner with Dexcel Pharma, its exclusive distributor for the Israeli market, to manufacture and package the product under Dexcel’s brand. Dexcel will handle sales, marketing, and distribution and share profits with Elite under specific conditions. The launch date for Elite’s generic Adderall® will depend on various factors, including licensee orders and manufacturing schedules.
For detailed information about ELTP stock, go to TipRanks’ Stock Analysis page.